LEGN Key Statistics, Chart & Performance
The current stock price of LEGN is 27.15 USD. In the past month the price decreased by -15.47%. In the past year, price decreased by -35.46%.
LEGN Latest News, Press Relases and Analysis
LEGN Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.29 | 405.44B | ||
| AMGN | AMGEN INC | 15.29 | 179.97B | ||
| GILD | GILEAD SCIENCES INC | 15.3 | 155.44B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.42 | 108.71B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.92 | 80.71B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 851.43 | 56.92B | ||
| INSM | INSMED INC | N/A | 43.74B | ||
| NTRA | NATERA INC | N/A | 32.75B | ||
| BIIB | BIOGEN INC | 10.56 | 25.92B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.08 | 21.58B | ||
| INCY | INCYTE CORP | 16.55 | 20.75B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.12B |
Related stock screener links
About LEGN
Company Profile
Legend Biotech Corp. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, manufacturing, and commercialization of novel therapies for oncology and other indications. The company is headquartered in Somerset, New Jersey and currently employs 2,800 full-time employees. The company went IPO on 2020-06-04. The firm is engaged in the discovery, development, manufacturing and commercialization of cell therapies for oncology and other indications. Its lead product candidate, ciltacabtagene autoleucel (cilta-cel), referred to as LCAR- B38M, is an autologous chimeric antigen receptor (CAR-T) cell therapy that targets the B-cell maturation antigen (BCMA), which is a highly expressed protein in several hematologic malignancies, including multiple myeloma (MM). In addition to cilta-cel, the Company has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, small cell lung cancer, and non-small cell lung cancer. The company is also engaged in developing an allogeneic gamma delta CAR-T product candidate and an allogeneic CAR-NK product candidate targeting BCMA for MM.
Company Info
LEGEND BIOTECH CORP-ADR
2101 Cottontail Lane
Somerset NEW JERSEY 08873 US
CEO: Ying Huang
Employees: 2600
Phone: 17328505598
LEGEND BIOTECH CORP-ADR / LEGN FAQ
What does LEGEND BIOTECH CORP-ADR do?
Legend Biotech Corp. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, manufacturing, and commercialization of novel therapies for oncology and other indications. The company is headquartered in Somerset, New Jersey and currently employs 2,800 full-time employees. The company went IPO on 2020-06-04. The firm is engaged in the discovery, development, manufacturing and commercialization of cell therapies for oncology and other indications. Its lead product candidate, ciltacabtagene autoleucel (cilta-cel), referred to as LCAR- B38M, is an autologous chimeric antigen receptor (CAR-T) cell therapy that targets the B-cell maturation antigen (BCMA), which is a highly expressed protein in several hematologic malignancies, including multiple myeloma (MM). In addition to cilta-cel, the Company has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, small cell lung cancer, and non-small cell lung cancer. The company is also engaged in developing an allogeneic gamma delta CAR-T product candidate and an allogeneic CAR-NK product candidate targeting BCMA for MM.
What is the current price of LEGN stock?
The current stock price of LEGN is 27.15 USD. The price decreased by -3.62% in the last trading session.
What is the dividend status of LEGEND BIOTECH CORP-ADR?
LEGN does not pay a dividend.
What is the ChartMill technical and fundamental rating of LEGN stock?
LEGN has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
Would investing in LEGEND BIOTECH CORP-ADR be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on LEGN.
What is the market capitalization of LEGN stock?
LEGEND BIOTECH CORP-ADR (LEGN) has a market capitalization of 4.98B USD. This makes LEGN a Mid Cap stock.
What is the outstanding short interest for LEGEND BIOTECH CORP-ADR?
The outstanding short interest for LEGEND BIOTECH CORP-ADR (LEGN) is 11.9% of its float.
LEGN Technical Analysis
LEGN Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to LEGN. LEGN scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
LEGN Financial Highlights
Over the last trailing twelve months LEGN reported a non-GAAP Earnings per Share(EPS) of -1.29. The EPS increased by 32.11% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -14.01% | ||
| ROE | -23.73% | ||
| Debt/Equity | 0.26 |
LEGN Forecast & Estimates
25 analysts have analysed LEGN and the average price target is 75.3 USD. This implies a price increase of 177.36% is expected in the next year compared to the current price of 27.15.
For the next year, analysts expect an EPS growth of -6.81% and a revenue growth 67.55% for LEGN